AU2022311961A1 - Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof - Google Patents
Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof Download PDFInfo
- Publication number
- AU2022311961A1 AU2022311961A1 AU2022311961A AU2022311961A AU2022311961A1 AU 2022311961 A1 AU2022311961 A1 AU 2022311961A1 AU 2022311961 A AU2022311961 A AU 2022311961A AU 2022311961 A AU2022311961 A AU 2022311961A AU 2022311961 A1 AU2022311961 A1 AU 2022311961A1
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- bifunctional compound
- cell
- cdk4
- helios
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163222646P | 2021-07-16 | 2021-07-16 | |
| US63/222,646 | 2021-07-16 | ||
| PCT/US2022/073782 WO2023288305A1 (en) | 2021-07-16 | 2022-07-15 | Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022311961A1 true AU2022311961A1 (en) | 2023-11-09 |
Family
ID=84919760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022311961A Pending AU2022311961A1 (en) | 2021-07-16 | 2022-07-15 | Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240376096A1 (https=) |
| EP (1) | EP4370126A4 (https=) |
| JP (1) | JP2024525740A (https=) |
| CN (1) | CN117396208A (https=) |
| AU (1) | AU2022311961A1 (https=) |
| CA (1) | CA3217661A1 (https=) |
| WO (1) | WO2023288305A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118420612A (zh) * | 2023-02-01 | 2024-08-02 | 沈阳药科大学 | 一种基于cdk4/6抑制剂的靶向蛋白降解化合物及制备方法和用途 |
| WO2025245178A1 (en) * | 2024-05-21 | 2025-11-27 | Innovo Therapeutics, Inc. | Pak4, cstf2, or cstf2t protein degraders, pharmaceutical compositions, and therapeutic applications |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04005939A (es) | 2002-01-22 | 2005-01-25 | Warner Lambert Co | 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas. |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| US20090030005A1 (en) * | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combinations for the treatment of cancer |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| TW201014830A (en) | 2008-09-30 | 2010-04-16 | Theravance Inc | Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid |
| US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
| WO2013039854A1 (en) | 2011-09-15 | 2013-03-21 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| MX386473B (es) | 2013-02-21 | 2025-03-18 | Pfizer | Formas solidas de un inhibidor de cdk4/6 selectivo |
| CN107530292B (zh) | 2015-04-16 | 2022-11-01 | 诺华股份有限公司 | 瑞博西尼片剂 |
| CA3018429A1 (en) * | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use |
| AU2018351050B2 (en) * | 2017-10-18 | 2025-09-18 | Novartis Ag | Compositions and methods for selective protein degradation |
| WO2019196812A1 (zh) * | 2018-04-09 | 2019-10-17 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
| CA3123519A1 (en) * | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
-
2022
- 2022-07-15 CN CN202280039096.5A patent/CN117396208A/zh active Pending
- 2022-07-15 CA CA3217661A patent/CA3217661A1/en active Pending
- 2022-07-15 US US18/577,531 patent/US20240376096A1/en active Pending
- 2022-07-15 AU AU2022311961A patent/AU2022311961A1/en active Pending
- 2022-07-15 EP EP22843071.6A patent/EP4370126A4/en active Pending
- 2022-07-15 WO PCT/US2022/073782 patent/WO2023288305A1/en not_active Ceased
- 2022-07-15 JP JP2024501799A patent/JP2024525740A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4370126A1 (en) | 2024-05-22 |
| CA3217661A1 (en) | 2023-01-19 |
| US20240376096A1 (en) | 2024-11-14 |
| EP4370126A4 (en) | 2025-05-28 |
| WO2023288305A1 (en) | 2023-01-19 |
| JP2024525740A (ja) | 2024-07-12 |
| CN117396208A (zh) | 2024-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12110292B2 (en) | Ligands to cereblon (CRBN) | |
| EP4034132B1 (en) | Erk5 degraders as therapeutics in cancer and inflammatory diseases | |
| US20240376096A1 (en) | Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof | |
| EP4051386A1 (en) | Small molecule degraders of helios and methods of use | |
| EP3883573B1 (en) | Macrocyclic inhibitors of dyrk1a | |
| IL301690A (en) | Piperidinyl small molecule degraders of helios and methods of use | |
| EP3814330A1 (en) | Immunomodulatory compounds | |
| WO2020069106A1 (en) | Degraders that target alk and therapeutic uses thereof | |
| EP4367115A1 (en) | Degraders of wild-type and mutant forms of lrrk2 and uses thereof | |
| WO2020210451A1 (en) | Degraders of fibroblast growth factor receptor 2 (fgfr2) | |
| WO2020069118A1 (en) | Macrocyclic inhibitors of alk, trka, trkb, and ros1 | |
| AU2021297778A1 (en) | Compounds for targeted degradation of interleukin-2-inducible T-cell kinase and methods of use |